152 related articles for article (PubMed ID: 10716066)
1. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations.
Devissaguet JP; Brion N; Lhote O; Deloffre P
Eur J Drug Metab Pharmacokinet; 1999; 24(3):265-71. PubMed ID: 10716066
[TBL] [Abstract][Full Text] [Related]
2. Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms.
Mattsson LA; Christiansen C; Colau JC; Palacios S; Kenemans P; Bergeron C; Chevallier O; Von Holst T; Gangar K
Am J Obstet Gynecol; 2000 Mar; 182(3):545-52. PubMed ID: 10739506
[TBL] [Abstract][Full Text] [Related]
3. [Aerodiol: the efficacy and tolerability of intranasal estrogen administration. An overview].
Genazzani AR; Cappagli B; Ciaponi M
Minerva Ginecol; 2003 Jun; 55(3):189-200. PubMed ID: 14581864
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of estradiol and of estrone during repeated transdermal or oral administration of estradiol.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1996 Aug; 46(8):766-73. PubMed ID: 9125276
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group.
Studd J; Pornel B; Marton I; Bringer J; Varin C; Tsouderos Y; Christiansen C
Lancet; 1999 May; 353(9164):1574-8. PubMed ID: 10334256
[TBL] [Abstract][Full Text] [Related]
6. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
7. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
8. Estradiol and estrone plasma levels during application of three strengths of a 7-day estradiol transdermal patch.
Setnikar I; Rovati LC; Santoro A; Guillaume M; Mignot A; Renoux A; Gualano V
Arzneimittelforschung; 1999 Aug; 49(8):708-15. PubMed ID: 10483519
[TBL] [Abstract][Full Text] [Related]
9. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.
Delmas PD; Marianowski L; Perez Ade C; Ribot C; Pornel B; Palacios S; Lopes P;
Maturitas; 2004 Jun; 48(2):85-96. PubMed ID: 15172082
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioequivalence studies with Estradot and Menorest transdermal systems.
Hossain M; Quebe-Fehling E; Sergejew T; Schmidt G; Skerjanec A; Cohen A; Krinsky L; Ibarra de Palacios P
Maturitas; 2003 Nov; 46(3):187-98. PubMed ID: 14585521
[TBL] [Abstract][Full Text] [Related]
11. 17beta-estradiol matrixpatch removal and reapplication in postmenopausal women: experimental results.
Rohr UD; Saeger-Lorenz K
J Pharm Sci; 2002 Mar; 91(3):810-21. PubMed ID: 11920767
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Fem7, a once-weekly, transdermal oestrogen replacement system in healthy, postmenopausal women.
Geyer D; Gerrits MG; Renoux A; Uhl W
Gynecol Obstet Invest; 1999; 48(1):1-6. PubMed ID: 10394083
[TBL] [Abstract][Full Text] [Related]
13. Pulsed estrogen therapy: from cellular mode of action to tissue effects.
Al-Azzawi F
Climacteric; 2002 Jun; 5 Suppl 2():27-31. PubMed ID: 12482108
[TBL] [Abstract][Full Text] [Related]
14. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet.
Järvinen A; Nykänen S; Paasiniemi L
Maturitas; 1999 Jun; 32(2):103-13. PubMed ID: 10465378
[TBL] [Abstract][Full Text] [Related]
15. Steady-state pharmacokinetics following application of a novel transdermal estradiol spray in healthy postmenopausal women.
Morton TL; Gattermeir DJ; Petersen CA; Day WW; Schumacher RJ
J Clin Pharmacol; 2009 Sep; 49(9):1037-46. PubMed ID: 19628730
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of continuous once-a-week combination 17β-Estradiol/Low- or high-dose levonorgestrel transdermal delivery systems in postmenopausal women.
Karara AH; Harrison LI; Melikian AP; Poola N; Morrison D; Bourg D; Bourg L; Zurth C
J Clin Pharmacol; 2014 May; 54(5):520-7. PubMed ID: 24474034
[TBL] [Abstract][Full Text] [Related]
17. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches.
Reginster JY; Donazzolo Y; Brion N; Lins R
Climacteric; 2000 Sep; 3(3):168-75. PubMed ID: 11910618
[TBL] [Abstract][Full Text] [Related]
18. Minimized estradiol absorption with ultra-low-dose 10 microg 17beta-estradiol vaginal tablets.
Eugster-Hausmann M; Waitzinger J; Lehnick D
Climacteric; 2010 Jun; 13(3):219-27. PubMed ID: 20423242
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of follicle stimulating hormone (FSH) in postmenopausal women during pulsed estrogen therapy: Evidence that FSH release and synthesis are controlled by distinct pathways.
Christin-Maitre S; Laveille C; Collette J; Brion N; Reginster JY
J Clin Endocrinol Metab; 2003 Nov; 88(11):5405-13. PubMed ID: 14602781
[TBL] [Abstract][Full Text] [Related]
20. The influence of the route of administration of 17beta-estradiol, intravenous (pulsed) versus oral, upon DMBA-induced mammary tumour development in ovariectomised rats.
Kerdelhué B; Jolette J
Breast Cancer Res Treat; 2002 May; 73(1):13-22. PubMed ID: 12083627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
